Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

  • Showing results for a modified search because your search retrieved no results.
1.

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

Bjerre C, Vinther L, Belling KC, Würtz SØ, Yadav R, Lademann U, Rigina O, Do KN, Ditzel HJ, Lykkesfeldt AE, Wang J, Nielsen HB, Brünner N, Gupta R, Schrohl AS, Stenvang J.

Tumour Biol. 2013 Dec;34(6):3839-51. doi: 10.1007/s13277-013-0969-7. Epub 2013 Jul 24.

PMID:
23881388
2.

Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor.

Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, Smith SL, Mahoney CJ, Shioda K, Isselbacher KJ, Ramaswamy S, Shioda T.

Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14536-41. doi: 10.1073/pnas.0907560106.

3.

Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.

Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS.

Growth Horm IGF Res. 2006 Aug;16(4):224-39. Epub 2006 Aug 8.

PMID:
16893667
4.

Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.

Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K.

J Steroid Biochem Mol Biol. 2003 May;85(1):33-47.

PMID:
12798355
5.

Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.

Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV.

Clin Cancer Res. 2004 Aug 1;10(15):5215-25.

6.

MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.

Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP.

Oncogene. 2011 Mar 3;30(9):1082-97. doi: 10.1038/onc.2010.487. Epub 2010 Nov 8.

8.

Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.

Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.

Mol Cancer Res. 2008 Aug;6(8):1347-55. doi: 10.1158/1541-7786.MCR-07-2179.

9.

Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.

Tsuboi K, Kaneko Y, Nagatomo T, Fujii R, Hanamura T, Gohno T, Yamaguchi Y, Niwa T, Hayashi SI.

J Steroid Biochem Mol Biol. 2017 Mar;167:115-125. doi: 10.1016/j.jsbmb.2016.11.017. Epub 2016 Nov 22.

PMID:
27888136
10.

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.

Endocr Relat Cancer. 2006 Dec;13(4):1121-33.

12.

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.

Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS.

Oncogene. 2016 Mar 3;35(9):1143-52. doi: 10.1038/onc.2015.169. Epub 2015 Jul 6. Erratum in: Oncogene. 2016 Mar 3;35(9):1206.

13.

Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.

Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T.

PLoS One. 2013 Apr 4;8(4):e60889. doi: 10.1371/journal.pone.0060889. Print 2013.

15.

WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation.

Banerjee S, Saxena N, Sengupta K, Tawfik O, Mayo MS, Banerjee SK.

Neoplasia. 2003 Jan-Feb;5(1):63-73.

16.

An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.

Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC.

Mol Cell Endocrinol. 1992 Dec;90(1):77-86.

PMID:
1301400
17.

interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).

Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Riggins RB, Cao D, Clarke R.

Cancer Res. 2004 Jun 1;64(11):4030-9.

18.

Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.

Chen Y, Li Z, He Y, Shang D, Pan J, Wang H, Chen H, Zhu Z, Wan L, Wang X.

Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.

PMID:
24440569
19.
20.

Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).

Gu Z, Lee RY, Skaar TC, Bouker KB, Welch JN, Lu J, Liu A, Zhu Y, Davis N, Leonessa F, Brünner N, Wang Y, Clarke R.

Cancer Res. 2002 Jun 15;62(12):3428-37.

Supplemental Content

Support Center